Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post-marketing study (J-STEP/EL Study).

ABSTRACT:

Aims/introduction

Although sodium-glucose cotransporter 2 inhibitors are a promising treatment for type 2 diabetes mellitus, they are associated with concerns about specific adverse drug reactions. We carried out a 1-year post-marketing study of tofogliflozin, a novel agent in this class, in Japanese elderly patients with type 2 diabetes mellitus.

Materials and methods

This was a prospective, observational and multicenter post-marketing study carried out in the context of routine clinical practice. The study included all type 2 diabetes patients aged ≥65 years who started treatment with tofogliflozin during the first 3 months after its launch on 23 May 2014.

Results

Of 1,535 patients registered, 1,507 patients whose electronic case report forms were collected and who

SUBMITTER: Utsunomiya K 

PROVIDER: S-EPMC5668483 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature